By Lara Goulson, licensed independent insurance agent, Goulson Insurance Services, Los Angeles
For years, the answer to whether Medicare paid for a weight-loss drug was a flat no, and the reason was statutory rather than clinical. Medicare Part D was barred from covering a drug prescribed for weight loss alone. Not discouraged from it — barred. That one line of law is why two people could stand at the same pharmacy counter holding prescriptions for the identical medication and pay wildly different amounts. That changed on July 1, 2026, though not in the way most of the coverage suggested. The change is narrower than the headlines, it has an expiration date, and its eligibility rules contain a real surprise. According to CMS (Centers for Medicare and Medicaid Services), the GLP-1 Bridge demonstration program represents a significant but time-limited shift in how Medicare approaches obesity pharmacotherapy — and understanding its boundaries matters as much as understanding its benefits.
